Barr’s Rationale For Pliva Merger: Business Synergy, Biogenerics Leadership

Barr is highlighting its complementary product portfolio and business model in its efforts to ward off competition from Actavis to acquire Pliva

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet